Latest news and press releases about Agenus Inc. (AGEN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies.
Price
| Price | $7.21 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 2.68 |
| Price / Book | -1.51 |
| EV / EBITDA | 2.34 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.12% |
| Return on Invested Capital | -129.48% |
| Return on Assets | 53.28% |
| Gross Margin | 75.63% |
| Operating Margin | 27.28% |
| Net Margin | 69.34% |
Related companies: ABOS · FATE · HURA · INO · IRD · PLRX · SEER
Explore sector: Healthcare · Biotechnology
More sections of AGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks